Content Spotlight
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
Pfizer has refused to comment on claims made by the Irish press it is investing €1 billion ($1 billion) in its Grange Castle biomanufacturing site.
The 90-acre manufacturing site in Clondalkin in Dublin was opened in 2006 following a $2 billion investment by Wyeth (which Pfizer acquired in 2009). The site has benefitted from continual investments and expansion since, including a $40 million mRNA expansion to support the firm’s COVID-19 vaccine efforts.
But now Pfizer could be ready to invest €1 billion into the site, according to the Business Post. The outlet reported Saturday that construction of a new biomanufacturing facility will begin next summer, with completion set for the end of 2026.
Image: DepositPhotos/
ventanamedia
However, when contacted by BioProcess Insider, Pfizer refused to comment on the proposed investment:
“We do not comment on speculation,” a spokesperson said. “Pfizer is constantly assessing our manufacturing network to ensure we can continue to bring our breakthroughs to patients.”
You May Also Like